skip navigationU S P T O SealUnited States Patent and Trademark Office AOTW logo
Home|Site Index|Search|Guides|Contacts|eBusiness|eBiz alerts|News|Help
Assignments on the Web > Patent Query
Patent Assignment Abstract of Title
NOTE:Results display only for issued patents and published applications. For pending or abandoned applications please consult USPTO staff.

Total Assignments: 3
Patent #:
NONE
Issue Dt:
Application #:
15499523
Filing Dt:
04/27/2017
Publication #:
Pub Dt:
11/02/2017
Inventors:
Leo Pavliv, James West, Ines Macias-Perez, Erica Carrier
Title:
IFETROBAN TREATMENT FOR SYSTEMIC SCLEROSIS
Assignment: 1
Reel/Frame:
042354/0200Recorded: 05/12/2017Pages: 6
Conveyance:
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).
Assignors:
Exec Dt:
05/02/2017
Exec Dt:
05/09/2017
Exec Dt:
05/02/2017
Exec Dt:
05/09/2017
Assignees:
2525 WEST END AVENUE
STE 950
NASHVILLE, TENNESSEE 37203
2201 WEST END AVENUE
305 KIRKLAND HALL
NASHVILLE, TENNESSEE 37240
Correspondent:
DAVIDSON, DAVIDSON & KAPPEL, LLC
589 EIGHTH AVENUE
16TH FLOOR
NEW YORK, NY 10018
Assignment: 2
Reel/Frame:
061163/0965Recorded: 08/12/2022Pages: 2
Conveyance:
CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS).
Assignor:
Exec Dt:
08/01/2022
Assignee:
NIH DIVISION OF EXTRAMURAL INVENTIONS AND TECHNOLOGY RESOURCES (DEITR)
6705 ROCKLEDGE DRIVE, SUITE 310, MSC 7980
BETHESDA, MARYLAND 20892-7980
Correspondent:
DIRECTOR, DEITR
NIH, 6705 ROCKLEDGE DRIVE, SUITE 310
MSC 7980
BETHESDA, MD 20892-7980
Assignment: 3
Reel/Frame:
063705/0757Recorded: 05/19/2023Pages: 2
Conveyance:
CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS).
Assignor:
Exec Dt:
05/15/2023
Assignee:
6705 ROCKLEDGE DRIVE
BETHESDA, MARYLAND 20892-7974
Correspondent:
CHRIS HARRIS
1207 17TH AVENUE SOUTH, SUITE 105
NASHVILLE, TN 37212

Search Results as of: 05/13/2024 08:53 AM
If you have any comments or questions concerning the data displayed, contact PRD / Assignments at 571-272-3350. v.2.6
Web interface last modified: August 25, 2017 v.2.6
| .HOME | INDEX| SEARCH | eBUSINESS | CONTACT US | PRIVACY STATEMENT